Clinical and microbiological characteristics of eggerthella lenta bacteremia

Bradley J Gardiner, Alex Y C Tai, Despina Kotsanas, Michelle J Francis, Sally A Roberts, Susan Alicia Ballard, Ralph K Junckerstorff, Tony Korman

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82 ) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85 ), the median duration of treatment was 21.5 days. Mortality from all causes was 6 at 7 days, 12 at 30 days, and 33 at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91 were susceptible to clindamycin, 74 were susceptible to moxifloxacin, and 39 were susceptible to penicillin. ? 2015, American Society for Microbiology. All Rights Reserved.
Original languageEnglish
Pages (from-to)626 - 635
Number of pages10
JournalJournal of Clinical Microbiology
Volume53
Issue number2
DOIs
Publication statusPublished - 2015

Cite this

Gardiner, B. J., Tai, A. Y. C., Kotsanas, D., Francis, M. J., Roberts, S. A., Ballard, S. A., ... Korman, T. (2015). Clinical and microbiological characteristics of eggerthella lenta bacteremia. Journal of Clinical Microbiology, 53(2), 626 - 635. https://doi.org/10.1128/JCM.02926-14
Gardiner, Bradley J ; Tai, Alex Y C ; Kotsanas, Despina ; Francis, Michelle J ; Roberts, Sally A ; Ballard, Susan Alicia ; Junckerstorff, Ralph K ; Korman, Tony. / Clinical and microbiological characteristics of eggerthella lenta bacteremia. In: Journal of Clinical Microbiology. 2015 ; Vol. 53, No. 2. pp. 626 - 635.
@article{47bc9b44704c468eabe305b023078136,
title = "Clinical and microbiological characteristics of eggerthella lenta bacteremia",
abstract = "Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82 ) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85 ), the median duration of treatment was 21.5 days. Mortality from all causes was 6 at 7 days, 12 at 30 days, and 33 at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91 were susceptible to clindamycin, 74 were susceptible to moxifloxacin, and 39 were susceptible to penicillin. ? 2015, American Society for Microbiology. All Rights Reserved.",
author = "Gardiner, {Bradley J} and Tai, {Alex Y C} and Despina Kotsanas and Francis, {Michelle J} and Roberts, {Sally A} and Ballard, {Susan Alicia} and Junckerstorff, {Ralph K} and Tony Korman",
year = "2015",
doi = "10.1128/JCM.02926-14",
language = "English",
volume = "53",
pages = "626 -- 635",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

Gardiner, BJ, Tai, AYC, Kotsanas, D, Francis, MJ, Roberts, SA, Ballard, SA, Junckerstorff, RK & Korman, T 2015, 'Clinical and microbiological characteristics of eggerthella lenta bacteremia' Journal of Clinical Microbiology, vol. 53, no. 2, pp. 626 - 635. https://doi.org/10.1128/JCM.02926-14

Clinical and microbiological characteristics of eggerthella lenta bacteremia. / Gardiner, Bradley J; Tai, Alex Y C; Kotsanas, Despina; Francis, Michelle J; Roberts, Sally A; Ballard, Susan Alicia; Junckerstorff, Ralph K; Korman, Tony.

In: Journal of Clinical Microbiology, Vol. 53, No. 2, 2015, p. 626 - 635.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Clinical and microbiological characteristics of eggerthella lenta bacteremia

AU - Gardiner, Bradley J

AU - Tai, Alex Y C

AU - Kotsanas, Despina

AU - Francis, Michelle J

AU - Roberts, Sally A

AU - Ballard, Susan Alicia

AU - Junckerstorff, Ralph K

AU - Korman, Tony

PY - 2015

Y1 - 2015

N2 - Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82 ) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85 ), the median duration of treatment was 21.5 days. Mortality from all causes was 6 at 7 days, 12 at 30 days, and 33 at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91 were susceptible to clindamycin, 74 were susceptible to moxifloxacin, and 39 were susceptible to penicillin. ? 2015, American Society for Microbiology. All Rights Reserved.

AB - Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82 ) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85 ), the median duration of treatment was 21.5 days. Mortality from all causes was 6 at 7 days, 12 at 30 days, and 33 at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91 were susceptible to clindamycin, 74 were susceptible to moxifloxacin, and 39 were susceptible to penicillin. ? 2015, American Society for Microbiology. All Rights Reserved.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298500/pdf/zjm626.pdf

U2 - 10.1128/JCM.02926-14

DO - 10.1128/JCM.02926-14

M3 - Article

VL - 53

SP - 626

EP - 635

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -

Gardiner BJ, Tai AYC, Kotsanas D, Francis MJ, Roberts SA, Ballard SA et al. Clinical and microbiological characteristics of eggerthella lenta bacteremia. Journal of Clinical Microbiology. 2015;53(2):626 - 635. https://doi.org/10.1128/JCM.02926-14